Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5640
Source ID: NCT01990300
Associated Drug: Alogliptin/Pioglitazone
Title: Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT01990300/results
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Alogliptin/Pioglitazone
Outcome Measures: Primary: Number of Participants Who Experience at Least One Adverse Events, Up to 12 Months|Changes From Baseline in Glycosylated Hemoglobin (HbA1c), Reported data are changes in HbA1c from baseline at Month 1, 3, 6, 12 and final assessment (up to 12 months)., Baseline and Month 1, 3, 6, 12 and final assessment (up to 12 Months) | Secondary: Changes From Baseline in Fasting Blood Glucose (FBG), Reported data are changes in fasting blood glucose level from baseline at Month 1, 3, 6, 12 and final assessment (up to 12 months)., Baseline and Month 1, 3, 6, 12 and final assessment (up to 12 Months)
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: CHILD, ADULT, OLDER_ADULT
Phases:
Enrollment: 3281
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2011-11-28
Completion Date: 2015-03-31
Results First Posted: 2019-01-18
Last Update Posted: 2023-09-18
Locations: Someplace, Japan
URL: https://clinicaltrials.gov/show/NCT01990300